UNCY INVESTOR ALERT: Class Action Lawsuit Filed on Behalf of Unicycive Therapeutics, Inc. Investors – Holzer & Holzer, LLC Encourages Investors With Losses to Contact the Firm

ATLANTA, Sept. 04, 2026 -- A shareholder class action lawsuit has been filed against Unicycive Therapeutics, Inc. (“Unicycive”) (NASDAQ: UNCY). The lawsuit alleges that Defendants made false and misleading statements and/or failed to disclose material adverse facts, including allegations that: (1) Unicycive had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices; (2) as a result, Unicycive lacked a reasonable basis to believe that the vendor had resolved the FDA’s cited deficiencies; (3) there was an undisclosed risk that the FDA would require additional information about the vendor’s facility’s manufacturing practices; (4) as a result of the foregoing, the regulatory approval of oxylanthanum carbonate was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants’ positive statements about Unicycive’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.